Shares of OrthoPediatrics Corp. (NASDAQ:KIDS - Get Free Report) have been given a consensus recommendation of "Moderate Buy" by the seven research firms that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $35.83.
Several research analysts recently issued reports on KIDS shares. Piper Sandler dropped their price target on shares of OrthoPediatrics from $40.00 to $30.00 and set an "overweight" rating for the company in a research report on Thursday, May 8th. Truist Financial decreased their price objective on shares of OrthoPediatrics from $26.00 to $24.00 and set a "hold" rating on the stock in a research note on Friday, April 11th. Needham & Company LLC reaffirmed a "buy" rating and set a $42.00 price objective on shares of OrthoPediatrics in a research note on Thursday, May 8th. BTIG Research reaffirmed a "buy" rating on shares of OrthoPediatrics in a research note on Monday, July 14th. Finally, Lake Street Capital assumed coverage on shares of OrthoPediatrics in a research note on Monday, April 7th. They set a "buy" rating and a $37.00 price objective on the stock.
Check Out Our Latest Stock Analysis on OrthoPediatrics
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the business. Brown Advisory Inc. increased its stake in shares of OrthoPediatrics by 6.2% during the first quarter. Brown Advisory Inc. now owns 1,628,747 shares of the company's stock valued at $40,116,000 after buying an additional 94,719 shares during the period. Wellington Management Group LLP grew its stake in OrthoPediatrics by 20.2% in the fourth quarter. Wellington Management Group LLP now owns 1,061,299 shares of the company's stock valued at $24,601,000 after purchasing an additional 178,078 shares during the last quarter. Vanguard Group Inc. grew its stake in OrthoPediatrics by 1.5% in the first quarter. Vanguard Group Inc. now owns 937,969 shares of the company's stock valued at $23,102,000 after purchasing an additional 14,079 shares during the last quarter. Wasatch Advisors LP grew its stake in OrthoPediatrics by 47.2% in the fourth quarter. Wasatch Advisors LP now owns 696,318 shares of the company's stock valued at $16,141,000 after purchasing an additional 223,217 shares during the last quarter. Finally, Dimensional Fund Advisors LP grew its stake in OrthoPediatrics by 29.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 671,968 shares of the company's stock valued at $15,576,000 after purchasing an additional 152,681 shares during the last quarter. 69.05% of the stock is owned by hedge funds and other institutional investors.
OrthoPediatrics Price Performance
NASDAQ:KIDS traded up $0.88 during trading hours on Tuesday, hitting $22.76. 177,611 shares of the stock were exchanged, compared to its average volume of 197,299. The company has a market cap of $552.77 million, a P/E ratio of -13.01 and a beta of 1.10. OrthoPediatrics has a 52-week low of $19.52 and a 52-week high of $34.77. The company has a current ratio of 6.19, a quick ratio of 2.99 and a debt-to-equity ratio of 0.21. The firm's fifty day moving average price is $21.58 and its 200 day moving average price is $23.02.
OrthoPediatrics (NASDAQ:KIDS - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.13). The company had revenue of $52.41 million during the quarter, compared to analysts' expectations of $51.68 million. OrthoPediatrics had a negative net margin of 19.15% and a negative return on equity of 7.03%. As a group, equities research analysts anticipate that OrthoPediatrics will post -0.93 EPS for the current fiscal year.
OrthoPediatrics Company Profile
(
Get Free ReportOrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.
See Also
Before you consider OrthoPediatrics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OrthoPediatrics wasn't on the list.
While OrthoPediatrics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
